Clinical Trial Update: A Safety and Efficacy Trial of TTHX1114 in People With CED [Phase 2]

View source ↗

Summary

Phase 2 trial completed evaluating safety and efficacy of TTHX1114 for Corneal Endothelial Dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Endothelial Dystrophy

Drugs mentioned

• TTHX1114

Snippet

Sponsor: Trefoil Therapeutics, Inc. | Conditions: Corneal Endothelial Dystrophy | Phase 2 | Status: COMPLETED